Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Export to CSV
Displaying 76 - 100 of 1258
Please scroll or swipe to the right to view the full content.
Brand Name Generic Name Files Therapeutic Area Recommendation Type Status Submission Date Recommendation Date Project Number
Lumakras sotorasib
Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 KRAS G12C-mutated advanced NSCLC Do not reimburse Complete PC0300-000
Trecondyv treosulfan
Recommendation and ReasonsClinical, Pharmacoeconomic and Ethics combined ReportStakeholder feedback on Draft Recommendation
 Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Reimburse with clinical criteria and/or conditions Complete PC0324-000
Beqvez fidanacogene elaparvovec
Recommendation and ReasonsClinical, Pharmacoeconomic and Ethics combined ReportStakeholder feedback on Draft Recommendation
 Hemophilia B Reimburse with clinical criteria and/or conditions Complete SG0802-000
Rezurock belumosudil
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Graft-versus-host disease Reimburse with clinical criteria and/or conditions Complete SR0789-000
Bylvay odevixibat
Recommendation and ReasonsClinical, Pharmacoeconomic and Ethics combined ReportStakeholder feedback on Draft Recommendation
 Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Complete SR0788-000
Columvi glofitamab
Recommendation and ReasonsClinical and Pharmacoeconomic combined ReportStakeholder feedback on Draft Recommendation
 Relapsed or refractory diffuse large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete PC0320-000
Opdualag nivolumab and relatlimab
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 unresectable or metastatic melanoma Reimburse with clinical criteria and/or conditions Complete PC0329-000
Akeega niraparib abiraterone acetate
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete PC0326-000
Trodelvy sacituzumab govitecan
Recommendation and ReasonsClinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation
 HR+, HER2− advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete PC0323-000
Lynparza olaparib
Recommendation and ReasonsClinical and Pharmacoeconomic combined ReportStakeholder feedback on Draft Recommendation
 Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete PC0319-000
Amvuttra vutrisiran
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) Reimburse with clinical criteria and/or conditions Complete SR0801-000
Evkeeza evinacumab
Recommendation and ReasonsClinical, Pharmacoeconomic and Ethics combined ReportStakeholder feedback on Draft Recommendation
 Homozygous familial hypercholesterolemia (HoFH) Reimburse with clinical criteria and/or conditions Complete SR0778-000
N/A eltrombopag
Recommendation and ReasonsResponses to Questions From the Drug ProgramsClinical and Pharmacoeconomic Combined ReportStakeholder InputStakeholder Feedback on Draft Recommendation
 Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Complete SX0777-000
Imbruvica ibrutinib
Recommendation and ReasonsClinical and Pharmacoeconomic combined ReportStakeholder feedback on Draft Recommendation
 Waldenström’s Macroglobulinemia Reimburse with clinical criteria and/or conditions Complete PC0328-000
Asparlas calaspargase pegol
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Acute lymphoblastic leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete PC0321-000
Polivy polatuzumab vedotin
Recommendation and ReasonsClinical and Pharmacoeconomic combined ReportStakeholder feedback on Draft Recommendation
 Large B-cell lymphoma Do not reimburse Complete PC0313-000
N/A bevacizumab and lomustine
Recommendation and ReasonsResponses to Questions From the Drug ProgramsClinical and Pharmacoeconomic Combined ReportStakeholder Input - CliniciansStakeholder Input - IndustryStakeholder Feedback on Draft Recommendation
 Recurrent glioblastoma multiform Reimburse with clinical criteria and/or conditions Complete PX0318-000
Rinvoq upadacitinib
Recommendation and ReasonsClinical and Pharmacoeconomic combined ReportStakeholder feedback on Draft Recommendation
 Crohns disease Reimburse with clinical criteria and/or conditions Complete SR0775-000
Vyvgart efgartigimod alfa
Recommendation and ReasonsClinical and Pharmacoeconomic combined ReportStakeholder feedback on Draft Recommendation
 Generalized myasthenia gravis (gMG) Reimburse with clinical criteria and/or conditions Complete SR0782-000
Ondexxya andexanet alfa
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder feedback on Draft Recommendation
 Reversal of FXa inhibitor anticoagulant effects Do not reimburse Complete ST0772-000
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Cystic fibrosis, F508del CFTR mutation, 2 years and older Reimburse with clinical criteria and/or conditions Complete SR0776-000
Sogroya somapacitan
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Growth Hormone Deficiency (GHD) Reimburse with clinical criteria and/or conditions Complete SR0779-000
Omvoh mirikizumab
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete SR0773-000
Imfinzi and Imjudo durvalumab and tremelimumab
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 unresectable hepatocellular carcinoma Reimburse with clinical criteria and/or conditions Complete PC0308-000
Cabometyx cabozantinib
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Advanced or metastatic renal cell carcinoma Reimburse with clinical criteria and/or conditions Complete PC0312-000

Health Technology Review

Last Updated
Export to CSV
Displaying 76 - 100 of 589
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Sub Line Status Project Number
Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evaluation
Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evalua…
 Technology Review Completed MH0020-000
Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis
Final ReportProject Protocol
 Health Technology Assessment Completed HT0038-000
Utilization of Antidiabetic Drugs During Pregnancy
Technology Review In Progress HC0083-000 — OS0007-000
Drugs for Metastatic Renal Cell Carcinoma: Utilization Analysis
Technology Review Active HC0082-000
Newborn Screening for Congenital Cytomegalovirus in Canada Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood hearing loss. Our report provides a summary about newborn screening for cCMV in Canada, including whether screening is available in each province and territory, and if so, whether screening is universal or targeted.
Final Report
 Policy Insight Completed CY0016-000
Newborn Screening for Congenital Cytomegalovirus
Newborn Screening for Congenital Cytomegalovirus
 Rapid Review Completed RC1533-000
Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide-1 Receptor Agonists
Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide…Final Summary Report
 Technology Review Completed HC0087-000
Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)
Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)
 CMII Service Completed CM0010-000
General Ultrasound Examination Volumes per Sonographer 8-Hour Workday
General Ultrasound Examination Volumes per Sonographer 8-Hour Workday
 CMII Service Completed CM0012-000
Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada
Final Report, April 2024Summary Report, April 2024
 Technology Review Completed HC0069-000
Efficacy and Safety of Long-Term Use of Omalizumab for the Treatment of Chronic Idiopathic Urticaria
Final ReportFinal Summary ReportProject Protocol
 Systematic Review Active RE0043-000
SGLT2 inhibitors for the treatment of type 2 diabetes
Technology Review Cancelled HC0049-000
Renal Denervation
Renal Denervation
Rapid Review Completed RC1532-000
Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria
Final ReportFinal Summary Report
 Technology Review Completed HC0053-000
Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Technology Review In Progress HC0086 -000
NovoTTF-200A
Recommendation and ReasonsCADTH Summary ReportStakeholders InputSupplemental Materials report
 Optimal Use Completed OP0554-000
Utilization Analysis of Tofacitinib and Other Drugs Among Individuals With Ulcerative Colitis: Feasibility Analysis
Summary ReportFinal ReportProtocol: Utilization Analysis of Tofacitinib and Other Drugs Among Individuals…
 Observational Study Complete OS0003-000
Reprocessed Single-Use Semicritical and Critical Medical Devices We sought to identify and summarize literature evaluating the clinical safety of reprocessed single-used medical devices (SUMDs), defined as infections, mortality, or other adverse events, compared with nonreprocessed (new) SUMDs.
Reprocessed Single-Use Semicritical and Critical Medical Devices
Rapid Review Completed RC1511-000
Aerosol Therapy With Inhalers During Mechanical Ventilation
Aerosol Therapy With Inhalers During Mechanical Ventilation
Rapid Review Completed RC1529-000
Pan- Canadian Rare Disease Registries
Assessing Canadian Rare Disease Patient Registries for Real-World Evidence Usin…
 Environmental Scan Completed ES0369-000
Ketamine for Adults With Substance Use Disorders To inform decisions about using ketamine for treating SUDs, we sought to identify and summarize the literature comparing the clinical and cost-effectiveness of ketamine with placebo or no treatment, with alternative interventions, or among ketamine administered via different routes for SUDs.
Ketamine for Adults With Substance Use Disorders
Rapid Review Completed RC1523-000
Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle
Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle
Rapid Review Completed RC1528-000
Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery
Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery
Rapid Review Completed RC1530-000
Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults
Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults
 Technology Review Completed HE0047 -000
Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection
Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection
Rapid Review Completed RC1527-000

Horizon Scan

Last Updated
Export to CSV
Displaying 76 - 100 of 111
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Sub Line Status Project Number
COVID-19 Testing: A Summary of Testing Methods
COVID-19 Testing: A Summary of Testing Methods
 Emerging Health Technologies Completed EH0090-000
New Mechanical Thrombectomy Devices Designed to Treat Venous Thromboembolism
en0023-mechanical-thrombectomy-devices-article.pdf
Health Technology Update Completed EN0023-000
Non-Invasive Ventilation With Helmets for Acute Respiratory Distress Due to COVID-19
Non-Invasive Ventilation With Helmets for Acute Respiratory Distress Due to COV…
 Health Technology Update Completed EN0020-000
​Robotic Systems for Disinfecting Surfaces in Hospital Rooms and Other Health Care Environments
en0018-robotic-systems-for-disinfecting-surfaces.pdf
Health Technology Update Completed EN0018-000
A Virtual Waiting Room? Technologies That Limit Contact While Maintaining Patient Flow in Medical Practice Settings
en0019-topic1.pdf
Health Technology Update Completed EN0019-000
Salt-Based Technologies to Help Stop the Spread of the Coronavirus
Health Technology Update Completed EN0017-000
Biomarker-Based Point-of-Care Tests for the Evaluation of Mild Traumatic Brain Injury
Emerging Health Technologies Completed EH0084-000
Blood Purification Using Cytokine Adsorbers to Reduce Cytokine Storm in Severe COVID-19 Illness
Health Technology Update Completed EN0017-000
Health Technology Update Issue 26
EN0016-000
Saliva-Based Tests to Detect Active Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Health Technology Update Completed EN0017-000
Contact Tracing Apps to Identify Potential Exposure to SARS-CoV-2
Health Technology Update Completed EN0017-000
Health Technology Update - Issue 27
EN0017-000
Health Technology Update Issue 27
en0017-htu-issue27.pdf
EN0017-000
Smartphone-Connected Ultrasound Devices
Emerging Health Technologies Completed Eh0079-000
Early Identification of Ischemic Stroke
Emerging Health Technologies Completed EH0080-000
Endobronchial Valves for the Treatment of Severe Emphysema
Emerging Health Technologies Completed EH0083-000
Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
Emerging Health Technologies Completed EH0081-000
Lasmiditan for the Acute Treatment of Migraine
Emerging Health Technologies Completed EH0082-000
Horizon Scan Roundup — 2019
Roundup Completed ER0008-000
Minimally invasive therapies for benign prostatic hyperplasia (BPH)
Emerging Health Technologies Completed EH0078-000
Health Technology Update - Issue 26
Completed EN0016-000
Magnetic Resonance-Guided Radiotherapy: MR-Simulation and MR-Linac
Emerging Health Technologies Completed EH0074-000
Magnetic Resonance Guided Radiotherapy: MR-simulation, and MR-linac
Completed EH0074-000
Health Technology Update Issue 25
EN0015-000
Inclisiran: A Small Interfering RNA Molecule for Treating Hypercholesterolemia
Emerging Health Technologies Completed EH0076-000

Projects in Progress

Last Updated
Export to CSV
Displaying 26 - 40 of 40

View All Reports

Last Updated
Export to CSV
Displaying 76 - 100 of 2093
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Line Project Sub Line Status Project Number
olopatadine hydrochloride and mometasone
Draft RecommendationPatient and Clinician Group input
 Reimbursement Review Active SR0848-000
dupilumab
Patient and Clinician Group input
 Reimbursement Review Active SR0878-000
abemaciclib
Reimbursement Review Pending PC0400-000
abemaciclib
Reimbursement Review Pending PC0409-000
ruxolitinib
Draft Recommendation
 Reimbursement Review Active SR0807-000
Dupilumab
Patient and Clinician Group input
 Reimbursement Review Active SR0870-000
garadacimab
Patient and Clinician Group input
 Reimbursement Review Active SR0860-000
dupilumab
Patient and Clinician Group Input
 Reimbursement Review Active SR0876-000
cabotegravir
Recommendation and Reason Patient and Clinician Group InputClinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 Reimbursement Review Complete SR0825-000
talazoparib
Reimbursement Review Suspended PC0316-000
ravulizumab
Recommendation and Reason Patient and Clinician Group input
 Reimbursement Review Active SR0855-000
Dabrafenib trametinib
Proposed Scope
 Reimbursement Review Active PX0373-000
Chronic lymphocytic leukemia (CLL)
Draft Report
Reimbursement Review Provisional Funding Algorithm Active PH0063-000
iptacopan
Patient and Clinician Group input
 Reimbursement Review Active SR0851-000
rozanolixizumab
Patient and Clinician Group Input
 Reimbursement Review Active SR0846-000
lazertinib and amivantamab
Patient and Clinician Group input
 Reimbursement Review Active PC0392-000
inavolisib
Reimbursement Review Pending PC0382-000
Methadone for Surgical Patients
Methadone for Surgical Patients
Health Technology Review Rapid Review Completed RC1565-000
efanesoctocog alfa
Patient and Clinician Group Input
 Reimbursement Review Active ST0840-000
momelotinib
Draft RecommendationPatient and Clinician Group input
 Reimbursement Review Active PC0355-000
venetoclax
Reimbursement Review Pending PC0402-000
teplizumab
Reimbursement Review Pending SR0867-000
remdesivir
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 Reimbursement Review Complete SR0833-000
fidaxomicin
Proposed Scope
Reimbursement Review Active SX0754-000
nivolumab
Proposed Scope
 Reimbursement Review Active PX0376-000